Alvotech (ALVO) Financial Analysis & Valuation | Quarter Chart

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation bios... more
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worl... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$1.34BExchangeNASDAQ
SectorHealthcareIndustryDrug Manufacturers - Specialty & Generic
CountryISCEOLisa Graver
IPO Date2022-06-16CAGR62.44%
Employees1,279Websitewww.alvotech.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
ALVO chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$2.79BP/E-11.62Forward P/E15.89PEG
P/S7.38P/B-15.48P/CF-35.72P/FCF-24.12
Sales$559.42MSales 1Y-4.47%Sales 3Y468.28%Sales 5Y993.9%
EPS$-0.34EPS 1YEPS 3YEPS 5Y
Sales QoQ-36.37%EPS QoQ-100.72%Sales QoQ Avg1.47%EPS QoQ Avg520.43%
Gross Margin61.35%Operating Margin13.8%Profit Margin-14.43%ROCE6.65%
ROA-6%ROE35%Altman Z Score-1.45Piotroski Score2
Current Ratio1.76Quick Ratio0.88Cash Ratio0.25Op. CF Ratio-0.23
Debt/Equity-5.16Debt/Assets1.03Lt Debt/Equity-4.96Lt Debt/Cap.1.29
Intrst Cov.0.5Inventory Turnover0.95Asset Turnover0.39Receivables Turnover5.23
Enterprise Value$2.79BP/E Ratio-11.62
Forward P/E15.89PEG Ratio
P/S Ratio7.38P/B Ratio-15.48
P/CF Ratio-35.72P/FCF Ratio-24.12
EPS$-0.34EPS Growth 1Y
EPS Growth 3YEPS Growth 5Y
Revenue Growth 1Y-4.47%Gross Margin0.61%
Operating Margin0.14%Profit Margin-0.14%
ROE0.35%ROA-0.06%
ROCE0.07%Current Ratio1.76
Quick Ratio0.88Cash Ratio0.25
Debt/Equity-5.16Interest Coverage0.5
Altman Z Score-1.45Piotroski Score2

Alvotech (ALVO) valuation & financials

Alvotech (ALVO) has a market capitalization of $1.34B and trades at a price-to-earnings ratio of -11.6. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).

Alvotech's revenue grew -4.5% over the last year.

Alvotech's next earnings report is scheduled for August 19, 2026; analysts estimate EPS of $-0.06. Check the earnings calendar to see all companies reporting this week.

📈 Analysts estimate ALVO EPS of $-0.06 for the upcoming quarter. See Alvotech revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Alvotech (ALVO) — frequently asked questions

When does Alvotech (ALVO) report earnings next?

Alvotech is expected to report earnings on August 19, 2026. Analysts estimate EPS of $-0.06.

What is Alvotech's market cap?

Alvotech (ALVO) has a market capitalization of $1.34B.

What is ALVO's P/E ratio?

Alvotech trades at a price-to-earnings ratio of -11.6, with trailing twelve-month EPS of $-0.34.

How fast is Alvotech growing?

Alvotech's revenue grew -4.5% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)